Biologics contract development and manufacturing organizations (CDMO) have emerged as top merger and acquisition targets in the global biopharma industry and South Korean firms are actively taking part in the hunt, particularly for manufacturers that have capabilities in gene and cell therapies.
Of the 27 biopharma M&A transactions of 2021 worth at least $1bn, the top area of interest in terms of both volume and value was CDMOs/contract research organizations (CROs), which accounted for six transactions with an aggregate $56
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?